A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-center, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of CC-97489 in Healthy Adult Subjects
Latest Information Update: 20 Dec 2023
At a glance
- Drugs BMS 986368 (Primary)
 - Indications Neurological disorders
 - Focus Adverse reactions; First in man
 - Sponsors Celgene Corporation
 
Most Recent Events
- 08 Dec 2023 Status changed from recruiting to discontinued (Business objectives changed).
 - 03 Mar 2023 Planned End Date changed from 30 Dec 2022 to 26 Oct 2023.
 - 03 Mar 2023 Planned primary completion date changed from 30 Dec 2022 to 26 Oct 2023.